LFWD Lifeward Ltd.
Price Chart
Executive Summary
Lifeward reported Q1 2026 revenue of $3.9M (down 22% YoY) and a GAAP net loss of $10.8M ($6.70/share), massively missing the single-analyst consensus EPS estimate of -$0.34. The headline miss is driven by a one-time $4.9M non-cash acquired in-process R&D charge from the Oratech acquisition, but core operations also weakened: AlterG revenue fell 38% due to working capital constraints, gross margin contracted to 34.2% from 42.2%, and the GAAP operating loss more than doubled to $10.3M. The company delayed its 10-Q filing, adding uncertainty.
Key Financial Metrics
Actionable Insight
The massive EPS miss is largely non-cash and non-recurring, but the 22% revenue decline and 38% AlterG drop signal real operational headwinds from working capital constraints. The delayed 10-Q filing adds uncertainty. Watch for the Q2/Q3 shipment catch-up on secured AlterG orders and the ORMD-0801 Phase 2 trial start as potential catalysts. The $11.4M cash position provides a runway, but the company is burning ~$3.7M/quarter in operations.
Key Facts
- Revenue fell 22% YoY to $3.9M, missing the $5.8M consensus
- GAAP EPS of -$6.70 vs consensus -$0.34 — a 958.8% miss driven by a $4.9M non-cash IPR&D charge from the Oratech acquisition
- Non-GAAP adjusted net loss was $5.1M ($3.13/share), compared to $4.6M ($5.28/share) in Q1 2025
- AlterG revenue declined 38% to $2.1M due to working capital constraints affecting sourcing and supply chain
- Gross margin contracted to 34.2% from 42.2% YoY, driven by lower production volumes, tariffs, and FX
- Cash used in operations improved to $3.7M from $5.5M YoY; cash balance rose to $11.4M from $2.2M at year-end 2025, boosted by $10M financing and $6.5M cash from Oratech acquisition
- Company delayed filing of its Q1 2026 10-Q, citing need for additional time to finalize accounting related to the strategic transaction
- ReWalk personal exoskeleton sales increased 11% to $1.6M; MyoCycle FES bike sales flat at $0.2M
- Weighted average shares outstanding nearly doubled to 1.6M from 0.87M YoY, reflecting the reverse split and equity issuance
Financial Impact
Revenue miss of ~$1.9M (33% below consensus); GAAP EPS miss of $6.36 vs consensus; operating loss doubled to $10.3M; gross margin down 800 bps
Risk Factors
- Delayed 10-Q filing may trigger Nasdaq listing compliance concerns or covenant issues
- Working capital constraints continue to impair AlterG supply chain and revenue
- Integration of Oratech and execution on the oral insulin pipeline are unproven
- Dilution from the convertible notes and warrant liabilities ($6.8M) could pressure the stock
- Revenue concentration in AlterG (54% of total) leaves the company exposed to further supply chain disruptions
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295802 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 19, 2026
26d ago
|
8-K
| $6.40 $7.12 | ▲ +11.17% | ▲ +8.93% | $6.78 (+5.94%) |
|
May 15, 2026
4w ago
|
8-K
| $6.70 $7.05 | ▼ −5.22% | ▼ −4.26% | $6.78 (−1.19%) |
|
May 15, 2026
4w ago
|
Press Release
| $6.70 $7.05 | ▼ −5.22% | ▼ −4.26% | $6.78 (−1.19%) |
|
May 13, 2026
4w ago
|
EFFECT
| $6.63 $6.40 | ▲ +3.47% | ▲ +2.31% | $6.78 (−2.26%) |
|
May 11, 2026
4w ago
|
Press Release
| $6.40 $6.58 | ▲ +2.81% | ▲ +2.90% | $6.78 (+5.94%) |
|
Apr 27, 2026
6w ago
|
S-3
| $7.09 $7.08 | ▲ +0.21% | ▲ +1.90% | $6.78 (+4.37%) |
|
Mar 27, 2026
11w ago
|
3
| $6.31 $6.58 | ▲ +4.28% | ▼ −0.02% | $6.78 (+7.45%) |
|
Mar 27, 2026
11w ago
|
3
| $6.31 $6.58 | ▲ +4.28% | ▼ −0.02% | $6.78 (+7.45%) |
|
Mar 25, 2026
11w ago
|
Press Release
| $6.30 $6.86 | ▲ +8.89% | ▲ +7.26% | $6.78 (+7.62%) |
|
Mar 18, 2026
12w ago
|
8-K
| $6.72 $6.53 | ▼ −2.83% | ▼ −2.11% | $6.78 (+0.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access